Delivered by Zelestra’s in-house EPC team in under 14 months, the projects supported around 400 jobs during construction. Now operational, they are expected to avoid more than 42,700 tons of CO2 emissions annually.
In total, 275,000 solar modules were installed across the three plants, on a single-axis tracker system to maximise production.
Castilla-La Mancha is a key region for Zelestra in Spain, with 470 MW across 9 projects contracted with customers, and a wider development pipeline of over 360 MW of solar, wind and BESS projects.
The Belinchón projects are backed by a long-term multi-buyer power purchase agreement (PPA) through the Energise programme, a supply chain decarbonisation initiative managed by Schneider Electric.
Energise brings together leading pharmaceutical companies, sponsored by Takeda Pharmaceuticals International AG, Teva Pharmaceutical Industries, and UCB, alongside suppliers, Avantor, Organon LLC, Perrigo, and West Pharmaceutical Services Inc. The collaboration supports reductions in scope 2 and scope 3 emissions across the pharmaceutical value chain.
“The Belinchón cluster is a significant new addition to our global portfolio of operational projects and it’s also a major project supporting Spain’s clean energy transition” said Luis Alvargonzalez, Zelestra’s Country Manager in Spain. “It is a strong example of how we deliver projects quickly and efficiently. It also demonstrates how we are supporting industrial decarbonisation, and I am proud of the positive impact Belinchón will deliver for the pharmaceutical sector across Spain and wider in Europe.”
In Spain, Zelestra has 1.1 GW of multi-tech clean energy projects contracted with customers and a wider development pipeline exceeding 7 GW. Globally its EPC division has delivered approximately 3.5 GW of projects and includes a team of more than 300 specialists.
For additional information:
